The future of diabetes may be restoring beta-cell differentiation as opposed to promoting insulin production, says award-winning researcher at the 2014 ICE/ENDO conference in Chicago.
- Posted June 24, 2014 by Beta Cells in Diabetes Staff
- Posted November 19, 2013 by Doron Schneider, MD, FACP
Obstructive sleep apnea is a common and underdiagnosed condition in patients with type 2 diabetes. This blog post explores what is known about the underlying mechanism that may relate sleep apnea to diabetes.
- Posted August 6, 2013 by Irl B. Hirsch, MDOver the past six months we have had more questions than answers about the risk of incretin therapy (DPP-4 inhibitors and GLP-1 agonists) and the increased risks for both pancreatitis and pancreatic carcinoma. The discussion seems to have resolved to an interim and perhaps temporary conclusion based on the recent American Diabetes Association Scientific Sessions in Chicago in June.At that conference Dr.
- Posted June 12, 2013 by John L. Leahy, MD
Doron Schneider, MD and Jack Leahy, MD discuss the importance of patient BMI and other risk factors for coronary artery disease when weighing treatment options.
- Posted March 19, 2013 by Doron Schneider, MD, FACPIt is certainly a new world. As a result of healthcare reform the landscape of diabetes care has forever been altered. The practicing clinician, patient and healthcare administrators all need to have a firm grasp of these new realities if they wish to prosper now and into the future. In this blog post I intend to provide a high level overview of the different ways that diabetes care is affected in this brave new world.Patients· Insurance coverage – patients will now be provided expanded insurance
- Posted March 18, 2013 by Jay Shubrook, DO, FACOFP, FAAFP
There is almost no other disease as pervasive as type 2 diabetes, a disease that has touched almost every family in America. Although there was a time when we had limited management tools, we now have ten classes of medications plus many kinds of insulin available as options. The result is a choice of many treatment combinations, which, however welcome, can also be overwhelming for the practicing physician. With so many choices it becomes very hard to decide what comes after metformin.
The Good, The Bad, and the Ugly Part II: Why I’m not a Fan of the ADA/EASD’s 2012 Position StatementPosted June 6, 2012 by John L. Leahy, MD
- Posted May 30, 2012 by John L. Leahy, MDThe highly awaited ADA/EASD statement on management of type 2 diabetes was published online April 19th, 2012.1 I feel like a curmudgeon,but as a general statement, I’m not a fan. In fact, I’m worried that at best it will have little impact, and at worst could be harmful.
- Posted March 28, 2012 by John L. Leahy, MD
In the past decade or so, our attempts to define the "earliest” events in Type 2 diabetes (T2DM) have moved increasingly earlier. We’re considering even the years before what we now consider to be the “pre-diabetes” stage—that is, years considerably before there are any clinical signs or symptoms of disease.
- Page 1 of 3